Individuals Stopping Slimming Injections Gain Back Weight Four Times Faster Compared to Those on Conventional Diets

New research indicates that patients who stop using popular GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who end traditional lifestyle plans.

Research printed in a prominent medical journal demonstrates that while obese people can lose a large proportion of their total mass while on the medication, the mass is regained at an average rate of 0.8 kg per month once they quit.

"People using these treatments need to be informed of the potential of quick rebound weight gain when the medication concludes," cautioned researcher Dr. Susan Jebb.

Such speed of recovery suggests a return to original weight within about one and a half years.

Weighing Treatments

The analysis, which reviewed 37 of trials involving thousands of patients, compared the effects of these new drugs with other pills.

Researchers emphasize that individuals who lose weight through dieting usually see a slower creep back—perhaps 0.1 kg a month—once they finish.

Understanding the Quick Regain

Experts propose the way of the drugs explains the accelerated regain.

The injections copy a body's own chemical called glucagon-like peptide-1, which controls hunger.

"Artificially providing GLP-1 levels several times higher than normal might result in the body to produce less of its endogenous hormone, and may also reduce sensitivity to its effects," noted Dr. Adam Collins, a dietetics expert.

"Withdrawal of this GLP-1 'fix' leads to appetite is uncontrolled, making binge eating much more probable."

A Chronic Issue?

Medical guidelines advise the injections for people with weight-linked health risks, alongside prescribed diet and exercise modifications.

Professionals say that, considering the significant potential of relapse, the treatment is often long-term.

This view is supported by drug manufacturers, who say that the findings "underscore the chronic character of obesity," comparing it to managing conditions like diabetes.

Patient Testimonies

Users who have stopped the jabs explain a intense resurgence of appetite.

"It was like something flipping and I was suddenly ravenous," described one woman.

This challenge is compounded if users have not adopted lasting dietary or behavioural modifications during treatment.

Significant Use

Recent estimates indicate that a significant number of adults in the UK have used these injections in the past year, with desire being substantial.

• Use is greater among females than men.
• The 40s and 50s demographic shows the greatest level of interest.
• A large proportion obtain the drugs through private healthcare rather than the NHS.

Finally, researchers emphasize that while the jabs are effective agents for shedding pounds, they are not a magic cure and lasting health benefits likely depends on ongoing behavioural support.